Kidney Cancer Journal | Volume 4, Issue 3
The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice...
Read MoreSelect Page
by Kidney Cancer Journal | Oct 2020
The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice...
Read Moreby Kidney Cancer Journal | Jul 2020
Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma Abstract With the...
Read Moreby Kidney Cancer Journal | Apr 2020
The Prognostic Value of DNA Methylation Markers in Renal Cell Cancer: A Systematic Review...
Read Moreby Kidney Cancer Journal | Nov 2019
Immune Checkpoint Inhibition, the Key to Success in Renal Cell Carcinoma?Treatment of renal cell...
Read Moreby Kidney Cancer Journal | Oct 2019
Genomic Instability in Kidney Cancer: Etiologies and Treatment Opportunities Genomic instability...
Read Moreby Kidney Cancer Journal | Aug 2019
The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the...
Read Moreby Kidney Cancer Journal | Apr 2019
Radiation Therapy for Renal Cell Carcinoma Radiation therapy (RT) has traditionally been...
Read Moreby Samit D. Soni, MD | Dec 2018
Samit Soni, MD, discusses challenges encountered during robotic partial nephrectomy and various tools and techniques that can improve outcomes. In addition, he demonstrates traditional transperitoneal and retroperitoneoscopic techniques for access to the kidney for partial nephrectomy, noting relative indications for each approach.
Read Moreby Kidney Cancer Journal | Sep 2018
Partial Nephrectomy is the Surgical Treatment of Choice for (Most) Complex Localized Renal...
Read Moreby Peter G. Schulam, MD, PhD | May 2018
Peter Schulam, MD, PhD, reviews the controversy surrounding prostate cancer screening, explains the literature that led to the United States Preventive Services Task Force (USPSTF) coming out with a C recommendation for prostate cancer screening, and notes the limitations in the current standard of transrectal ultrasound (TRUS) biopsy. He then discusses how MRI fusion biopsy could address these limitations.
Read Moreby Peter G. Schulam, MD, PhD | May 2018
Peter Schulam MD, PhD, emphasizes the importance of staging renal tumors based on weighted risk, including risk of metastases, histologic subtypes, and adverse pathologic characteristics, and not simply mass size. This is essential when considering partial nephrectomy, radical nephrectomy, active surveillance, ablative techniques, or other management options for individual patients.
Read Moreby Kidney Cancer Journal | Apr 2018
Adjuvant Sunitinib for Renal Cell Carcinoma: Still at the Beginning of the RoadThe remarkable...
Read More